Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials
出版年份 2023 全文链接
标题
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials
作者
关键词
-
出版物
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-13
出版商
Informa UK Limited
发表日期
2023-10-09
DOI
10.1080/14787210.2023.2268287
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies
- (2023) Yulong Chi et al. Expert Review of Anti-Infective Therapy
- Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams
- (2023) Milo Gatti et al. Expert Review of Anti-Infective Therapy
- Continuous infusion of beta-lactam antibiotics: narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy
- (2023) Jason A. Roberts et al. Expert Review of Anti-Infective Therapy
- Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020
- (2023) Morgan A Alford et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13
- (2023) George G Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020
- (2023) Heather J Adam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry
- (2023) George Zhanel et al. Journal of Global Antimicrobial Resistance
- CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy
- (2023) Ivan Gentile et al. International Journal of Antimicrobial Agents
- Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study
- (2023) Davide Fiore Bavaro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy
- (2022) Joseph P. Lynch et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Infections Due to Acinetobacter baumannii–calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options
- (2022) Joseph P. Lynch et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections
- (2022) Jesús Sojo-Dorado et al. JAMA Network Open
- The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante’s Forest Dark
- (2022) Pranita D. Tamma et al. JAMA Network Open
- New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
- (2022) Truc T. Tran et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Escalation of antimicrobial resistance among MRSA part 2: focus on infections and treatment
- (2022) Joseph P. Lynch et al. Expert Review of Anti-Infective Therapy
- Escalation of antimicrobial resistance among MRSA part 1: focus on global spread
- (2022) Joseph P. Lynch et al. Expert Review of Anti-Infective Therapy
- Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies
- (2021) Roberta Maria Antonello et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry
- (2021) George G. Zhanel et al. Journal of Global Antimicrobial Resistance
- Escalating Antimicrobial Resistance Among Enterobacteriaceae: Focus on Carbapenemases
- (2021) Joseph P. Lynch et al. EXPERT OPINION ON PHARMACOTHERAPY
- Real-life experience with ceftolozane/tazobactam in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry
- (2021) George G. Zhanel et al. Journal of Global Antimicrobial Resistance
- Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- (2021) Jaesh Naik et al. Infectious Diseases and Therapy
- Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
- (2021) Milo Gatti et al. Drug Design Development and Therapy
- A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients
- (2021) Yatin Mehta et al. Indian Journal of Critical Care Medicine
- Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon
- (2021) Tala Ballouz et al. Journal of Infection in Developing Countries
- Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections
- (2021) Tasneem A.K. Abdallah et al. Journal of Infection and Public Health
- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- (2020) Antonio Vena et al. CLINICAL INFECTIOUS DISEASES
- Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
- (2020) Kamal Hamed et al. Future Microbiology
- Real life experience with Ceftobiprole in a tertiary care hospital
- (2020) Emanuele Durante-Mangoni et al. Journal of Global Antimicrobial Resistance
- Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series
- (2020) Ebrahim Mahmoud et al. Infection and Drug Resistance
- Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies
- (2020) Roberta Maria Antonello et al. Antibiotics-Basel
- Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis
- (2020) Nuria Monteagudo-Martínez et al. Expert Review of Anti-Infective Therapy
- Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
- (2020) Rosario Cultrera et al. Antibiotics-Basel
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
- (2019) George G. Zhanel et al. DRUGS
- Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
- (2019) Thomas W. L. Scheeren et al. BMC INFECTIOUS DISEASES
- Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa
- (2019) Benoît Pilmis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Current clinical use of intravenous fosfomycin in ICU patients in two European countries
- (2019) C. Putensen et al. INFECTION
- Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1500 mg Infusion
- (2019) Urania Rappo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of MRSA in Canada from 2007 to 2016
- (2019) Kimberly A Nichol et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016
- (2019) Andrew J Denisuik et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007–16
- (2019) Alyssa R Golden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007–16
- (2019) Philippe R S Lagacé-Wiens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study
- (2019) George G Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–15
- (2018) James A Karlowsky et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study
- (2018) Andrew J Denisuik et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
- (2018) Abdulrahman Elabor et al. Open Forum Infectious Diseases
- In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16
- (2017) Andrew Walkty et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
- (2016) George G. Zhanel et al. DRUGS
- Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults
- (2016) Coleman Rotstein et al. Canadian Journal of Infectious Diseases & Medical Microbiology
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
- (2014) S. S. Awad et al. CLINICAL INFECTIOUS DISEASES
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
- (2014) Helen W. Boucher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistantStaphylococcus aureus
- (2013) Ahmed Hamed Salem et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
- (2012) George G Zhanel et al. Expert Review of Anti-Infective Therapy
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
- (2012) Susan C. Nicholson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- New Lipoglycopeptides
- (2010) George G. Zhanel et al. DRUGS
- Ceftobiprole
- (2009) George G Zhanel et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Ceftaroline
- (2009) George G. Zhanel et al. DRUGS
- Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
- (2009) G. G. Zhanel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started